GSK’s malaria vaccine trial successful
Britain’s pharmaceutical giant GaxoSmithKline (GSK) has successfully conducted the trial of the RTS,S vaccine developed by the company. In the results of the trial it was found that the vaccine nearly halved the cases of malaria experienced by children aged between five and seven months and cut the number of cases in babies aged 6 to 12 weeks by a quarter.
How would the RTS,S vaccine help?
Around 660,000 people die from malaria every year, most of them small children under the age of five. There are about 219 million cases of the disease a year worldwide, and children who survive the serious illness can suffer damage to their health and development in their lifetime afterwards. A vaccine, like RTS,S, could significant reduce the number of cases and deaths from this disease.